Reply to "Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real-World Evidence".

Saved in:
Bibliographic Details
Title: Reply to "Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real-World Evidence".
Authors: Cerono G; Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, USA., Cree BAC; Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, USA., Hauser SL; Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, USA., Baranzini SE; Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, USA.
Source: Annals of neurology [Ann Neurol] 2026 Jun; Vol. 99 (6), pp. 1614-1615. Date of Electronic Publication: 2026 Apr 07.
Publication Type: Letter
Journal Info: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 7707449 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1531-8249 (Electronic) Linking ISSN: 03645134 NLM ISO Abbreviation: Ann Neurol Subsets: MEDLINE; In Process
Database: MEDLINE Ultimate
Description
ISSN:1531-8249
DOI:10.1002/ana.78222